The glamour and gloom of glycogen synthase kinase-3

Trends in Biochemical Sciences

Volumn 29, Issue 2, 2004, Pages 95-102

  Jope, Richard S ^a   Johnson, Gail V W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3;

ALZHEIMER DISEASE; APOPTOSIS; CELL GROWTH; CELL MOTILITY; CELL STRUCTURE; CELL SURVIVAL; CELLULAR DISTRIBUTION; COMPLEX FORMATION; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBSTRATE; INSULIN RESISTANCE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

EID: 0442276554     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2003.12.004     Document Type: Review

References (71)

1. Mukai F., et al. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β J. Neurochem. 81:2002;1073-1083.
2. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359:2001;1-16.
3. Tanji C., et al. A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3β (GSK-3β) and mediates protein kinase A-dependent inhibition of GSK-3β J. Biol. Chem. 277:2002;36955-36961.
4. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog. Neurobiol. 65:2001;391-426.
5. Bijur G.N., Jope R.S. Glycogen synthase kinase-3β is highly activated in nuclei and mitochondria. NeuroReport. 14:2003;2415-2419.
6. Diehl J.A., et al. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:1998;3499-3511.
7. Bijur G.N., Jope R.S. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3β J. Biol. Chem. 276:2001;37436-37442.
8. Bijur G.N., Jope R.S. Dynamic regulation of mitochondrial Akt and GSK3β J. Neurochem. 87:2003;1427-1435.
9. Manoukian A.S., Woodgett J.R. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv. Cancer Res. 84:2002;203-229.
10. Price M.A., Kalderon D. Proteolysis of the hedgehog signaling effector cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1. Cell. 108:2002;823-835.
11. Jia J., et al. Shaggy/GSK antagonizes hedgehog signaling by regulating cubitus interruptus. Nature. 416:2002;548-552.
12. Franca-Koh J., et al. The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP. J. Biol. Chem. 277:2002;43844-43848.
13. Watcharasit P., et al. Direct, activating interaction between glycogen synthase kinase-3β and p53 after DNA damage. Proc. Natl. Acad. Sci. U. S. A. 99:2002;7951-7955.
14. Fujimuro M., et al. A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat. Med. 9:2003;300-306.
15. Watcharasit P., et al. Glycogen synthase kinase-3β (GSK3β) binds to, and promotes the actions of, p53. J. Biol. Chem. 278:2003;48872-48879.
16. Etienne-Manneville S., Hall A. Cdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity. Nature. 421:2003;753-756.
17. Eickholt B.J., et al. An inactive pool of GSK-3 at the leading edge of growth cones is implicated in semaphorin 3A signaling. J. Cell Biol. 157:2002;211-217.
18. Lucas F.R., et al. Inhibition of GSK-3β leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J. Cell Sci. 111:1998;1351-1361.
19. Hall A.C., et al. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell. Neurosci. 20:2002;257-270.
20. Sayas C.L., et al. Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3. Biochim. Biophys. Acta. 1582:2002;144-153.
21. Morfini G., et al. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 21:2002;281-293.
22. Wakefield J.G., et al. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J. Cell Sci. 116:2003;637-646.
23. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 273:1998;19929-19932.
24. Loberg R.D., et al. Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J. Biol. Chem. 277:2002;41667-41673.
25. Perez M., et al. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase-3. Biochem. J. 372:2003;129-136.
26. Song L., et al. Central role of glycogen synthase kinase-3β in endoplasmic reticulum stress-induced caspase-3 activation. J. Biol. Chem. 277:2002;44701-44708.
27. Carmichael J., et al. Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277:2002;33791-33798.
28. Kim H.S., et al. Regulation of angiogenesis by glycogen synthase kinase-3β J. Biol. Chem. 277:2002;41888-41896.
29. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8455-8459.
30. Chuang D.M., et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. 4:2002;129-136.
31. Bijur G.N., et al. Glycogen synthase kinase-3β facilitates staurosporine- and heat shock-induced apoptosis: protection by lithium. J. Biol. Chem. 275:2000;7583-7590.
32. Li X., et al. Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disord. 4:2002;137-144.
33. Cross D.A., et al. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77:2001;94-102.
34. Pap M., Cooper G.M. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β signaling pathway. Mol. Cell. Biol. 22:2002;578-586.
35. Kim J.W., et al. Glycogen synthase kinase 3β is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J. Biol. Chem. 278:2003;13995-14001.
36. Hongisto V., et al. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol. Cell. Biol. 23:2003;6027-6036.
37. Hoeflich K.P., et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature. 406:2000;86-90.
38. Schotte P., et al. Lithium sensitizes tumor cells in an NF-κB-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). J. Biol. Chem. 276:2001;25939-25945.
39. Schwabe R.F., Brenner D.A. Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 283:2002;G204-G211.
40. Demarchi F., et al. Glycogen synthase kinase-3β regulates NF-κB1/p105 stability. J. Biol. Chem. 278:2003;39583-39590.
41. Aubert J., et al. Functional gene screening in embryonic stem cells implicates Wnt antagonism in neural differentiation. Nat. Biotechnol. 20:2002;1240-1245.
42. Ding S., et al. Synthetic small molecules that control stem cell fate. Proc. Natl. Acad. Sci. U. S. A. 100:2003;7632-7637.
43. Hardt S.E., Sadoshima J. Glycogen synthase kinase-3β: a novel regulator of cardiac hypertrophy and development. Circ. Res. 90:2002;1055-1063.
44. Haq S., et al. Stabilization of β-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc. Natl. Acad. Sci. U. S. A. 100:2003;4610-4615.
45. Hill M.M., Hemmings B.A. Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol. Ther. 93:2002;243-251.
46. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry. 4:1999;117-128.
47. Phiel C.J., Klein P.S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41:2001;789-813.
48. Kozlovsky N., et al. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur. Neuropsychopharmacol. 12:2002;13-25.
49. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8:2002;126-132.
50. Nikoulina S.E., et al. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes. 49:2000;263-271.
51. Lochhead P.A., et al. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes. 50:2001;937-946.
52. Coghlan M.P., et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7:2000;793-803.
53. MacAulay K., et al. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur. J. Biochem. 270:2003;3829-3838.
54. Plotkin B., et al. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. 305:2003;974-980.
55. Ring D.B., et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 52:2003;588-595.
56. Henriksen E.J., et al. Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am. J. Physiol. Endocrinol. Metab. 284:2003;E892-E900.
57. Nikoulina S.E., et al. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes. 51:2002;2190-2198.
58. Phiel C.J., et al. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature. 423:2003;435-439.
59. Kang D.E., et al. Presenilin 1 facilitates the constitutive turnover of β-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the β-catenin signaling pathway. J. Neurosci. 19:1999;4229-4237.
60. Palacino J.J., et al. Presenilin 1 regulates β-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. J. Biol. Chem. 276:2001;38563-38569.
61. Pigino G., et al. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 23:2003;4499-4508.
62. Cho J.-H., Johnson G.V.W. Glycogen synthase kinase 3β phosphorylates tau at both primed and unprimed sites: differential impact on microtubule binding. J. Biol. Chem. 278:2003;187-193.
63. Frame S., et al. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell. 7:2001;1321-1327.
64. Dajani R., et al. Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 105:2001;721-732.
65. Jimbo T., et al. Identification of a link between the tumour suppressor APC and the kinesin superfamily. Nat. Cell Biol. 4:2002;323-327.
66. Johnson G.V.W., Bailey C.D.C. Tau, where are we now? J. Alzheimers Dis. 4:2002;375-398.
67. Ferrer I., et al. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. (Berl.). 104:2002;583-591.
68. Hernandez F., et al. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J. Neurochem. 83:2002;1529-1533.
69. Spittaels K., et al. Glycogen synthase kinase-3β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275:2000;41340-41349.
70. Sun X., et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321:2002;61-64.
71. Leroy K., et al. The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol. (Berl.). 103:2002;91-99.